In matched women, pooled PTH analogs including abaloparatide had 12 jaw osteonecrosis events versus 11 with romosozumab, without significant difference.
In plain wordsIn matched women, pooled PTH analogs including abaloparatide showed no significant difference in jaw osteonecrosis risk versus romosozumab.
- Peptide
- Abaloparatide (Tymlos)
- Outcome
- No significant changeMedication-related jaw osteonecrosis
- Study
n = 31,378
- Comparator
- Romosozumab
- Outcome group
- Adverse events · Musculoskeletal
Measurements
- MRONJ events
- 12 patients
- PTH analogs
- MRONJ events
- 11 patients
- romosozumab
- MRONJ rate
- 0.076%
- PTH analogs
- MRONJ rate
- 0.07%
- romosozumab
- Hazard ratio
- 0.89 ratio
- romosozumab versus PTH analogs
- Lower confidence bound
- 0.39 ratio
- 95% CI
- Upper confidence bound
- 2.01 ratio
- 95% CI
Source sentences
During 1 year of follow-up, MRONJ occurred in 11 romosozumab-treated patients and 12 PTH analog-treated patients (hazard ratio [HR] 0.89, 95% CI 0.39-2.01; log-rank p = 0.78).
4 context sentences(design, population, supporting numbers)
Absolute event rates were very low in both groups (0.070% vs. 0.076%).
We performed a retrospective new-user active comparator propensity score-matched cohort study in the TriNetX Global Collaborative Network comparing women treated with romosozumab vs. parathyroid hormone (PTH) analogs (teriparatide or abaloparatide).
Women aged ≥ 18 years with no prior osteonecrosis, jaw inflammatory disease, oral/head-neck cancer, or radiation exposure and no recent exposure to chemotherapy were eligible.
After 1:1 propensity score matching, 15,689 patients remained in each cohort.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).